Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.

<h4>Background</h4>Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily c...

Full description

Bibliographic Details
Main Authors: Yuko Kanbayashi, Mayumi Shimizu, Yuichi Ishizuka, Shohei Sawa, Katsushige Yabe, Mayako Uchida
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0278823
_version_ 1811177193154281472
author Yuko Kanbayashi
Mayumi Shimizu
Yuichi Ishizuka
Shohei Sawa
Katsushige Yabe
Mayako Uchida
author_facet Yuko Kanbayashi
Mayumi Shimizu
Yuichi Ishizuka
Shohei Sawa
Katsushige Yabe
Mayako Uchida
author_sort Yuko Kanbayashi
collection DOAJ
description <h4>Background</h4>Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine.<h4>Objective</h4>To identify factors associated with non-response to naldemedine in cancer patients.<h4>Methods</h4>This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as "effective" in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study.<h4>Results</h4>Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007-0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129-0.966).<h4>Conclusion</h4>The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients.
first_indexed 2024-04-10T22:57:35Z
format Article
id doaj.art-0e2c5f5fc96c46ea914212ace43721a2
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-04-10T22:57:35Z
publishDate 2022-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-0e2c5f5fc96c46ea914212ace43721a22023-01-14T05:31:42ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-011712e027882310.1371/journal.pone.0278823Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.Yuko KanbayashiMayumi ShimizuYuichi IshizukaShohei SawaKatsushige YabeMayako Uchida<h4>Background</h4>Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting μ-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine.<h4>Objective</h4>To identify factors associated with non-response to naldemedine in cancer patients.<h4>Methods</h4>This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as "effective" in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study.<h4>Results</h4>Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007-0.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129-0.966).<h4>Conclusion</h4>The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients.https://doi.org/10.1371/journal.pone.0278823
spellingShingle Yuko Kanbayashi
Mayumi Shimizu
Yuichi Ishizuka
Shohei Sawa
Katsushige Yabe
Mayako Uchida
Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
PLoS ONE
title Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
title_full Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
title_fullStr Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
title_full_unstemmed Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
title_short Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.
title_sort factors associated with non response to naldemedine for opioid induced constipation in cancer patients a subgroup analysis
url https://doi.org/10.1371/journal.pone.0278823
work_keys_str_mv AT yukokanbayashi factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis
AT mayumishimizu factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis
AT yuichiishizuka factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis
AT shoheisawa factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis
AT katsushigeyabe factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis
AT mayakouchida factorsassociatedwithnonresponsetonaldemedineforopioidinducedconstipationincancerpatientsasubgroupanalysis